Pain Relief,
according to AI
Every week we ask ChatGPT, Claude and Gemini the questions real UK consumers ask about pain relief — and record exactly which brands they put forward. Right now, Ibuprofen owns the conversation.
0 AI answers this run · 0 brands named · measured, never estimated
Ibuprofen is the default answer.
Named in 90% of pain relief answers, typically in position 1.9. Paracetamol follows at 72%, Aspirin at 40%.
Every brand AI names, ranked.
Visibility is the share of answers naming the brand; citation share is its slice of all brand-owned pages cited; read→cited is how often its pages convert a read into a citation.
| # | Brand | Visibility | Avg. position | Citation share | Read→cited |
|---|---|---|---|---|---|
| 1 | Ibuprofen | 90% | 1.9 | 0% | — |
| 2 | Paracetamol | 72% | 1.6 | 0% | — |
| 3 | Aspirin | 40% | 3.0 | 0% | — |
| 4 | Well | 23% | 2.8 | 0% | — |
| 5 | Nurofen | 13% | 4.4 | 50% | — |
| 6 | Panadol | 12% | 2.1 | 0% | — |
| 7 | Voltaren | 10% | 2.3 | 0% | — |
| 8 | Voltarol | 10% | 2.3 | 17% | 0% |
| 9 | Celebrex | 3% | 2.0 | 0% | — |
| 10 | Ibuleve | 3% | 3.5 | 0% | — |
| 11 | Biofreeze | 3% | 6.0 | 0% | — |
| 12 | Aleve | 2% | 1.0 | 0% | — |
| 13 | Anadin | 2% | 1.0 | 0% | — |
| 14 | Imigran | 2% | 1.0 | 0% | — |
| 15 | Arcoxia | 2% | 2.0 | 0% | — |
Ibuprofen is named most. That is not the same as being wanted.
Being named is visibility. Underneath it, every answer describes a brand in three ways — how much it stands out, how much it belongs, and how much it is returned to. In pain relief, Calpol leads attraction at 120 against Almus at 75, indexed on the category at 100.
Each whorl lights one ring per index threshold cleared. See the full pain relief desire edition →
The referees of pain relief.
The independent sources AI models cite when answering pain relief questions — the places a brand needs to be seen, reviewed and ranked.
The citation gap.
When Claude or ChatGPT opens a brand's own pages while answering, does the page make the cited-sources list? Too little read data in this category so far — the weekly runs will fill this in.
Full data table
| # | Brand | Visibility | Avg. position | Citation share | Read→cited |
|---|---|---|---|---|---|
| 1 | Ibuprofen | 90% | 1.9 | 0% | — |
| 2 | Paracetamol | 72% | 1.6 | 0% | — |
| 3 | Aspirin | 40% | 3.0 | 0% | — |
| 4 | Well | 23% | 2.8 | 0% | — |
| 5 | Nurofen | 13% | 4.4 | 50% | — |
| 6 | Panadol | 12% | 2.1 | 0% | — |
| 7 | Voltaren | 10% | 2.3 | 0% | — |
| 8 | Voltarol | 10% | 2.3 | 17% | 0% |
| 9 | Celebrex | 3% | 2.0 | 0% | — |
| 10 | Ibuleve | 3% | 3.5 | 0% | — |
| 11 | Biofreeze | 3% | 6.0 | 0% | — |
| 12 | Aleve | 2% | 1.0 | 0% | — |
| 13 | Anadin | 2% | 1.0 | 0% | — |
| 14 | Imigran | 2% | 1.0 | 0% | — |
| 15 | Arcoxia | 2% | 2.0 | 0% | — |
All three models agree: Ibuprofen.
A rare consensus — every model puts Ibuprofen first, and their top-five lists overlap 57%. Winning here means winning everywhere at once.
Brands whose visibility swings most between models — the bar per model, widest gap on the right.
The data behind this chart
| Brand | Claude | Gemini | ChatGPT | Spread |
|---|---|---|---|---|
| Aspirin | 35% | 30% | 55% | 25pp |
| Nurofen | 5% | 30% | 5% | 25pp |
| Paracetamol | 60% | 75% | 80% | 20pp |
| Celebrex | 10% | 0% | 0% | 10pp |
| Voltarol | 10% | 15% | 5% | 10pp |
| Voltaren | 10% | 15% | 5% | 10pp |
| Well | 25% | 25% | 20% | 5pp |
| Panadol | 10% | 15% | 10% | 5pp |
| Biofreeze | 5% | 5% | 0% | 5pp |
| Arcoxia | 5% | 0% | 0% | 5pp |
Editorial carry pain relief.
Every page AI opened while answering, classified by what kind of page it is. Editorial supply the most citations; Comparisons convert best — 93% of the ones models opened were actually cited.
The data behind this chart
| Page type | Cited | Read but not cited | Conversion |
|---|---|---|---|
| Editorial | 62 | 10 | 86% |
| How-to guides | 57 | 14 | 80% |
| Other | 21 | 12 | 64% |
| Comparisons | 14 | 1 | 93% |
| Listicles | 9 | 2 | 82% |
| Product pages | 9 | 1 | 90% |
| Documentation | 8 | 6 | 57% |
| spec-sheet | 8 | 4 | 67% |
Structured data is what separates cited from ignored.
Of the pain relief pages models actually opened, how much more often each feature's pages ended up in the cited sources. Structured data is worth 22 percentage points; hard statistics pages fare 20pp worse. Measured within the read population, so selection can't flatter it.
The data behind this chart
| Feature | Pages with | Cited % | Pages without | Cited % | Difference |
|---|---|---|---|---|---|
| Structured data | 185 | 86% | 87 | 64% | +22pp |
| Named author | 120 | 83% | 152 | 76% | +7pp |
| Comparison table | 47 | 83% | 225 | 79% | +4pp |
| Updated this year | 57 | 82% | 215 | 79% | +4pp |
| Answer up front | 134 | 81% | 138 | 78% | +2pp |
| Specifications | 36 | 75% | 236 | 80% | -5pp |
| Hard statistics | 58 | 64% | 214 | 84% | -20pp |
Nurofen builds pages AI can quote.
Readiness scores each brand's own pages on the structure models reward — a direct answer up front, tables, hard numbers, named authors, structured data, recency, specifications. Set against how often those pages are actually cited.
| Brand | Readiness | Pages cited | Pages profiled |
|---|---|---|---|
| Nurofen | 29 | 100% | 3 |
Readiness is the share of eight measurable structural signals present on a brand's profiled pages. It is a build-quality measure, not a ranking of the brand.
The questions pain relief pages have to settle.
Read straight off the pages AI cited: the consumer questions cited content answers most often. Content that fails to settle these is content models have no reason to quote.
Nineteen more categories.
Method: 20 unbranded consumer prompts per category, spread across the buying journey, run weekly against ChatGPT, Claude and Gemini. Read→cited uses Claude and ChatGPT only (Gemini does not separate the two). Correlational observations of model behaviour at the time of the run. Data from the run completed Tue, 01 Sep 2026 13:25:22 GMT.